lenalidomide
AbbVie and Genmab Move to Expand Use of T Cell Engager Epkinly Following Strong Phase III Results
Epkinly; epcoritamab; AbbVie; Genmab; follicular lymphoma; T cell engager; bispecific antibody; Phase III trial; FDA approval; label expansion; Rituximab; Lenalidomide